
About
United BioSource LLC (UBC) provides evidence development, safety and risk management, patient access, and clinical services for biopharma and healthcare providers. It supports specialty therapies including oncology, rare disease, cell therapy, and gene therapy for programs in the U.S. and globally. The company is headquartered in King of Prussia, Pennsylvania, with additional locations in Florida, Missouri, West Virginia, Switzerland, Spain, and the United Kingdom.
Services
Evidence Development
Generates real-world evidence for specialty therapies, including strategic consulting, research design, operational delivery, and regulatory-grade data analytics.
Integrated Evidence Generation Strategy
Develops evidence road maps and integrated evidence generation plans across the product lifecycle using stakeholder, regulatory, and market access inputs.
Modernized Study Design & Execution
Designs and executes hybrid and decentralized studies using digital capabilities, real-world evidence platforms, recruitment support, and data acquisition technologies.
Late-Stage Research
Supports registration and marketing authorization, post-marketing requirements, label expansion, publication strategy, expanded access, and market access evidence needs.
Safety & Risk Management
Provides drug safety, pharmacovigilance, and global risk management services, including REMS administration and regulatory-compliant safety support.
Patient Access
Supports access, affordability, and adherence programs to help patients obtain and stay on specialty therapies.
Clinical Services
Provides nursing network support for clinical research engagement and post-marketing medication adherence programs.
Healthcare Provider Study Investigator Support
Recruits and supports study investigators for clinical research participation and site engagement.
Technology Solutions
Offers proprietary software platforms for evidence development, safety and risk management, patient access, and data and analytics.
Capabilities
- Assays and studies
- Cell therapy · Real-world evidence · Observational research · Late-stage research · Pharmacovigilance · Risk evaluation and mitigation strategies (REMS) · Drug safety · Market access research · Patient adherence programs
- Scale and capacity
- More than 50% of active REMS · 3.8 million touches · 24,000 clinicians attended more than 43,000 unique training sessions · 25 sponsors in any given year · More than 50 different indications · 27 rare diseases · More than 5,600 combined home health agencies and injection center locations · Registered nurses in 40 countries · More than 90% of the U.S. population within reasonable driving distance of a UBC-trained clinician
- Therapeutic areas
- Oncology · Rare disease · Cell therapy · Gene therapy
Instruments and platforms
- UBC Evidence Engine
- CLÆRITY
- SæfetyWorks
- ExpressConnect
- UBC Pathways
- UBC REMS Platform
- UBC Electronic Data Capture
- UBC Epidemiology & Safety Software
- UBC Pathways Connected Health
- UBC Analytics
- UBC CTMS
- UBC Medication Cost & Utilization Software
- UBC eTMF (Veeva Vault, third-party)
- UBC Knowledge Survey System
- UBC Pathways Analytics
Modalities and species
- Modalities
- Cell therapy
- Species and models
- Healthcare providers · Patients · Site investigators · Nurses · Home health agencies · Injection centers
Company
- Type
- CRO
- Founded
- 2019
Locations
- Address
- 1000 Continental Drive, Suite 600 King of Prussia, PA 19406
- Sites
- King of Prussia, United States · Lake Mary, United States · Creve Coeur, United States · Morgantown, United States · Vernier, Switzerland · Madrid, Spain · Uxbridge, United Kingdom
- Serves
- United States, global
Similar labs
Work here? Claim this listing